Maravai LifeSciences (MRVI) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on May 26, 2026, with shareholders able to vote online, by phone, or by mail.

• Shareholders will vote on electing three directors, ratifying Deloitte & Touche LLP as auditor, and approving executive compensation on an advisory basis.

• Only shareholders of record as of March 27, 2026, are entitled to vote.

Voting matters and shareholder proposals

• Proposals include electing Bernd Brust, Gregory T. Lucier, and Luke Marker as directors for three-year terms, ratifying Deloitte & Touche LLP as auditor, and a non-binding say-on-pay vote for executive compensation.

• The board recommends voting FOR all proposals.

• Shareholder proposals for the 2027 meeting must be received by December 25, 2026, and director nominations by February 25, 2027.

Board of directors and corporate governance

• The board is divided into three classes, with eight directors post-2025, including four independent directors and three GTCR-affiliated directors.

• GTCR, as controlling shareholder, has significant nomination rights and board influence.

• The board relies on controlled company exemptions for certain Nasdaq governance requirements.

• The chairman is independent, and the board has Audit, Compensation, and Nominating committees.